UY27239A1 - Nuevos derivados de pirimidín-2,4,6-triona, procedimiento para su producción y agentes farmaceúticos que contienen estos compuestos. - Google Patents

Nuevos derivados de pirimidín-2,4,6-triona, procedimiento para su producción y agentes farmaceúticos que contienen estos compuestos.

Info

Publication number
UY27239A1
UY27239A1 UY27239A UY27239A UY27239A1 UY 27239 A1 UY27239 A1 UY 27239A1 UY 27239 A UY27239 A UY 27239A UY 27239 A UY27239 A UY 27239A UY 27239 A1 UY27239 A1 UY 27239A1
Authority
UY
Uruguay
Prior art keywords
compounds
pirimidín
triona
procedure
production
Prior art date
Application number
UY27239A
Other languages
English (en)
Inventor
D Geppert
F Grams
G Zimmermann
H-W Krell
H Leinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27239A1 publication Critical patent/UY27239A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos de fórmula I en donde R1 representa un radical de fenilo, fenoxilo, feniltilo, fenilsulfenilo, fenilsulfonilo, fenilamino o fenilmetilo sustituido o no sustituido, R2 es hidrógeno, r3 representa hidrógeno o alquilo, R4 representa alquilo, arilo, aralquilo, heterilo o acilo, y R2 y R3 o R3 y R4 forman un anillo de piperacina que puede estar sustituido, con actividad inhibidora de metaloproteinasa.
UY27239A 2001-03-30 2002-03-27 Nuevos derivados de pirimidín-2,4,6-triona, procedimiento para su producción y agentes farmaceúticos que contienen estos compuestos. UY27239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01107714 2001-03-30

Publications (1)

Publication Number Publication Date
UY27239A1 true UY27239A1 (es) 2002-09-30

Family

ID=8176973

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27239A UY27239A1 (es) 2001-03-30 2002-03-27 Nuevos derivados de pirimidín-2,4,6-triona, procedimiento para su producción y agentes farmaceúticos que contienen estos compuestos.

Country Status (15)

Country Link
US (1) US6716845B2 (es)
EP (1) EP1383746A2 (es)
JP (1) JP2004533425A (es)
KR (1) KR20030086335A (es)
CN (1) CN1273454C (es)
AR (1) AR035800A1 (es)
AU (1) AU2002302470C1 (es)
BR (1) BR0208440A (es)
CA (1) CA2442354A1 (es)
MX (1) MXPA03008588A (es)
PA (1) PA8542001A1 (es)
PE (1) PE20021101A1 (es)
UY (1) UY27239A1 (es)
WO (1) WO2002079170A2 (es)
ZA (1) ZA200306615B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8726714D0 (en) 1987-11-14 1987-12-16 Beecham Group Plc Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
DK0489579T3 (da) 1990-12-03 1995-06-12 Celltech Therapeutics Ltd Peptidylderivater
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
AU725831C (en) 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19726427A1 (de) * 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas

Also Published As

Publication number Publication date
AR035800A1 (es) 2004-07-14
CN1273454C (zh) 2006-09-06
JP2004533425A (ja) 2004-11-04
CA2442354A1 (en) 2002-10-10
US20020187991A1 (en) 2002-12-12
AU2002302470C1 (en) 2008-07-24
CN1553901A (zh) 2004-12-08
WO2002079170A3 (en) 2003-11-27
AU2002302470B2 (en) 2008-02-14
ZA200306615B (en) 2004-11-25
US6716845B2 (en) 2004-04-06
BR0208440A (pt) 2004-03-30
KR20030086335A (ko) 2003-11-07
MXPA03008588A (es) 2003-12-08
PE20021101A1 (es) 2003-02-13
WO2002079170A2 (en) 2002-10-10
PA8542001A1 (es) 2002-10-28
EP1383746A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
AR013199A1 (es) Compuesto sulfonamidas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de los mismos para la fabricacionde un medicamento
ES2029786T3 (es) Procedimiento para preparar nuevos derivados de quinolina.
AR009212A1 (es) Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen
DE69310501T2 (de) Chinolylbenzofuran derivate als leukotrien-antagonisten
DK345989A (da) Quinolinderivater
CO5550440A2 (es) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona,su preparacion y su aplicacion en terapeutica
DE69809187T2 (de) Metalloproteinase-Inhibitoren
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
DK0624584T3 (da) Piperazinderivater, der er nyttige som calmodulininhibitorer
SE8404712D0 (sv) Azole derivatives, process for their production compositions containing them and their use
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
CO5450245A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
DK0444659T3 (da) Farmaceutisk opløsning indeholdende derivater af FK 506
AR026351A1 (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii
ATE66240T1 (de) Phenolische korrosionsinhibitoren fuer anstrichstoffe.
PT83725B (pt) Processo para preparacao de novos derivados da 3-oxadiol-beta-carbolina e 3-carboxilato-beta-carbolina e de composicoes farmaceuticas que os contem
ATE9474T1 (de) Cephalosporinverbindungen und ihre herstellung.
AR015412A1 (es) Derivados de hidantoina que muestran una actividad inhibidora contra la farnesil transferasa, procedimiento para su preparacion y composicion anti-cancerque comprende a dichos derivados
UY27239A1 (es) Nuevos derivados de pirimidín-2,4,6-triona, procedimiento para su producción y agentes farmaceúticos que contienen estos compuestos.
CO4700450A1 (es) Nuevos azepanos y homologos de su anillo
AR004185A1 (es) Derivados de la piperinilmetiloxazolidin-2-ona, procedimiento para prepararlos, composiciones farmacéuticas que lo contienen y procedimiento para preparar estas composiciones farmcéuticas
AR013524A1 (es) Derivados aporfinoides, procesos para su produccion y agentes farmaceuticos que contienen estos compuestos
ATE259346T1 (de) Benflumentolderivative und ihre verwendung gegen parasitäre protozoen und trematoden
AR039175A1 (es) Derivados de morfolina, antagonistas de ccr3
ES2192104T3 (es) Compuestos de piridazinona condensados de tipo novedoso.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141126